31.66 USD
▲+0.11+0.35%
盘后 32.33 +2.12%
2026-11-19
市值
$2.21B
市盈率
—
EPS
-3.06
股息率
—
52 周区间
23.15 – 43.25
成交量
286.13K
Beta
-2.52
目标价
58.52
52W 低 23.1552W 高 43.25
价格走势
公司简介
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE a...